Trials / Completed
CompletedNCT03005080
Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease
The Utility of Pharmacogenetic Testing in Managing Children With Persistent Gastroesophageal Reflux Disease Despite Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 51 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.
Detailed description
This study will assess the clinical utility of pharmacogenomics testing in the clinical management of children with refractory GERD, despite adequate therapy and the role of pharmacogenomics in selecting the right acid suppressive therapy based on each patient's symptoms and pharmacogenomics results.
Conditions
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2018-10-01
- First posted
- 2016-12-29
- Last updated
- 2019-04-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03005080. Inclusion in this directory is not an endorsement.